Clinical Trial Update: Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update exploring radiotherapy in combination with almonertinib for stage III EGFR-mutated lung cancer (Phase 2/Phase 3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• Almonertinib (almonertinib)

Snippet

Sponsor: Laibin People's Hospital | Conditions: Lung Cancer Stage III | Phase 2, Phase 3 | Status: UNKNOWN